Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C21 InvestmentsCXXIF -0.09%31 ROC (Joel Greenblatt) % is 19.12% as of Mar. 2026, which is 45% above its 10-year median of 13.21. GuruFocus rates CXXIF with a GF Score™ of 31/100 and a GF Value™ of $0.28 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 983 Drug Manufacturers companies, C21 Investments ranks better than 59.21% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. C21 Investments's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 19.12%.
The historical rank and industry rank for C21 Investments's ROC (Joel Greenblatt) % or its related term are showing as below:
CXXIF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -222.34 Med: 13.21 Max: 142.23
Current: 16.51
During the past 13 years, C21 Investments's highest ROC (Joel Greenblatt) % was 142.23%. The lowest was -222.34%. And the median was 13.21%.
CXXIF's ROC (Joel Greenblatt) % is ranked better than 59.21% of 983
companies
in the Drug Manufacturers industry
Industry Median: 11.44
vs CXXIF: 16.51
C21 Investments's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -33.30% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
C21 Investments ROC (Joel Greenblatt) % Related Terms
C21 Investments ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for C21 Investments's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, C21 Investments's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C21 Investments ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, C21 Investments's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where C21 Investments's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 19.12% mean?
C21 Investments (CXXIF) has a ROC (Joel Greenblatt) % of 19.12% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on C21 Investments and its competitors. This is 45% above median its historical median of 13.21. According to the industry distribution chart, C21 Investments ranks #401 out of 983 companies in the Drug Manufacturers industry, placing it in the top 40.8%.
Is C21 Investments' ROC (Joel Greenblatt) % too high?
C21 Investments' current ROC (Joel Greenblatt) % of 19.12% is 45% above median its 10-year median of 13.21. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.44. C21 Investments' value of 19.12% is 67.1% above this industry median. Based on the distribution chart, C21 Investments ranks #401 out of 983 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, C21 Investments has a GF Score™ of 31/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does C21 Investments' ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, C21 Investments ranks #401 out of 983 companies for ROC (Joel Greenblatt) %. This puts C21 Investments in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.44. C21 Investments' value of 19.12% is 67.1% above this benchmark. While the company's 10-year median is 13.21 vs. the industry median of 11.44, C21 Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.44, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C21 Investments's current ROC (Joel Greenblatt) % of 19.12% is 67.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on C21 Investments and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C21 Investments's current ROC (Joel Greenblatt) % is 19.12%, which is 45% above median its own 10-year median of 13.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C21 Investments stock overvalued right now?
Based on GuruFocus' analysis, C21 Investments (CXXIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.28, compared to a current price of $0.21 — trading 23.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 19.12%, which is 45% above median its 10-year median of 13.21 and 67.1% above the Drug Manufacturers industry median of 11.44. C21 Investments' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For C21 Investments (CXXIF), the current ROC (Joel Greenblatt) % is 19.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C21 Investments (CXXIF) Overvalued in 2026?
Based on GuruFocus' analysis, C21 Investments stock appears to be undervalued.
The current stock price of $0.21 is trading 23.8% below its estimated GF Value™ of $0.28.
GuruFocus considers C21 Investments to be Modestly Undervalued.
Key valuation signals for CXXIF:
ROC (Joel Greenblatt) %: 19.12% (45% above median its 10-year median of 13.21)
GF Value™: $0.28 vs. price of $0.21 (23.8% below fair value)
Industry Position: 67.1% above the Drug Manufacturers median (#401 of 983)
No single metric tells the full story. See the CXXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C21 Investments Inc is a vertically integrated cannabis company that cultivates, processes, distributes, and sells quality cannabis and hemp-derived consumer products in Nevada, U.S.A., and the United States. The Company is focused on value creation through the disciplined acquisition and integration of core retail, manufacturing, and distribution assets in strategic markets, leveraging industry retail revenues with high-growth potential and multi-market branded consumer packaged goods (CPG). The Company focuses on scalable opportunities in key markets through retail operational excellence, expanding its retail footprint through value-add acquisitions in existing markets, and branded CPG expansion through captive retail and wholesale channels.
31GF Score
Get the complete analysis for CXXIF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CXXIF has been successfully added to your 
